乳腺癌DCE-MRI影像表现与VEGF、Her-2表达水平的关系研究

目的分析乳腺癌患者的术前动态增强磁共振成像(DCE-MRI)特点,探究其与血管内皮生长因子(VEGF)、人表皮生长因子受体-2(Her-2)表达水平的关系。方法 52例乳腺癌患者行术前DCEMRI扫描,分析其影像学特征,并检测术后切除肿瘤组织VEGF、Her-2表达情况,分析其与病灶MRI特点的关系。结果乳腺癌MRI特点为边缘多呈毛刺或不规则状、边界模糊,形态多不规则或分叶状,部分病灶出现坏死,呈不均匀或环形强化;大多癌灶T1W1呈略低信号,抑脂T2W1呈不均匀性高信号,注射对比剂增强扫描后信号明显均匀或斑驳样不均匀强化或环形强化;VEGF阳性表达率80%,Her-2阳性表达率76.67%;VEGF与乳腺癌MRI边缘毛刺(r=0.451,P=0.013)和早期边缘强化(r=0.843,P=0.001)呈显著正相关;Her-2与乳腺癌MRI病灶内部信号环形强化呈显著正相关(r=0.451,P=0.034)。结论乳腺癌DCEMRI影像表现与VEGF、Her-2表达具有一定相关性,MRI评估乳腺癌治疗和预后具有一定参考价值。

Study on the Relationship Between DCE-MRI Findings and Expression Levels of VEGF and Her-2 in Breast Cancer

Objective To analyze the dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) findings of patients with breast cancer before operation,and explore the relationship with expression levels of human vascular epidermal growth factor (VEGF)and human epidermal growth factor receptor-2 (Her-2).Methods DCE-MRI scan was performed in 52 patients with breast cancer before operation,and the imaging findings were analyzed.The expression of VEGF and Her-2 was detected,and the relationship with MRI was analyzed.Results MRI findings of breast cancer included edges in burr or irregular shape,fuzzy boundaries,irregular or lobulated shape,some lesions with necrosis,inhomogeneous or circular enhancement;Most of the tumors showed slightly low signal on T1W1,and inhomogeneous high signal on fat suppression T2W1.After injection of contrast agent,the enhanced scan showed obviously homogeneous or mottled inhomogeneous or circular enhancement;The positive expression rate of VEGF was 80％,and the positive expression rate of Her-2 was 76.67％;VEGF was significantly positively correlated with MRI burr (r=0.451,P=0.013) and early edge enhancement (r=0.843,P=0.001) in breast cancer,and Her-2 was significantly positively correlated with MIRI internal necrotic lesions (r=0.451,P=0.034).Concluion There is certain correlation between DCE-MRI findings of breast cancer and the expression of VEGF and Her-2,and MRI is of certain reference value in the treatment and prognosis of breast cancer.